TSOI
vs
S&P 500
TSOI
S&P 500
Over the past 12 months, TSOI has underperformed S&P 500, delivering a return of -50% compared to the S&P 500's +17% growth.
Stocks Performance
TSOI vs S&P 500
Performance Gap
TSOI vs S&P 500
Performance By Year
TSOI vs S&P 500
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Therapeutic Solutions International Inc
Glance View
Therapeutic Solutions International, Inc. engages in the manufacture of surgical and medical devices. The company is headquartered in Elk City, Idaho and currently employs 3 full-time employees. The company went IPO on 2008-06-09. The firm is engaged in developing a range of immune-modulatory agents to target certain cancers, schizophrenia, suicidal ideation, traumatic brain injury, lung pathologies, and for daily health. The company primarily produces nutraceuticals. Its lead product, QuadraMune, is a synergistic blend of pterostilbene, sulforaphane, epigallocatechin gallate, and thymoquinone. Its synergistic blend of ingredients helps the immune system fight off common and complex ailments and promotes healthy T-Cell activity. The firm also holds the rights to the development of adult stem cells for therapeutics in the areas of chronic traumatic encephalopathy (CTE) and traumatic brain injury (TBI) and lung pathology (LP). Its licensed stem cell, JadiCell, which possesses features of mesenchymal stem cells.
